Solubility profiling of HIV protease inhibitors in human intestinal fluids

Journal of Pharmaceutical Sciences

Volumn 102, Issue 10, 2013, Pages 3800-3807

  Wuyts, Benjamin ^a   Brouwers, Joachim ^a   Mols, Raf ^a   Tack, Jan ^b   Annaert, Pieter ^a   Augustijns, Patrick ^a  

^a DEPARTMENT OF PHARMACEUTICAL AND PHARMACOLOGICAL SCIENCES   (Belgium)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

FaSSIF; FeSSIF; Food interactions; HIV protease inhibitors; Human intestinal fluids; in vitro models; Intestinal absorption; Poorly water soluble drugs; Solubility

Indexed keywords

AMPRENAVIR; ATAZANAVIR; BILE ACID; DARUNAVIR; INDINAVIR; LOPINAVIR; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; PHOSPHOLIPID; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR; TIPRANAVIR;

ARTICLE; DRUG SOLUBILITY; FOOD INTAKE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTESTINE FLUID; PH; SOLID STATE;

FASSIF; FESSIF; FOOD INTERACTIONS; HIV PROTEASE INHIBITORS; HUMAN INTESTINAL FLUIDS; IN VITRO MODELS; INTESTINAL ABSORPTION; POORLY WATER-SOLUBLE DRUGS; SOLUBILITY;

ADULT; BILE ACIDS AND SALTS; BODY FLUIDS; EATING; FASTING; FEMALE; FOOD-DRUG INTERACTIONS; GASTROINTESTINAL CONTENTS; HIV PROTEASE INHIBITORS; HUMANS; HYDROGEN-ION CONCENTRATION; INTESTINES; MALE; MICELLES; POSTPRANDIAL PERIOD; RITONAVIR; SOLUBILITY; YOUNG ADULT;

EID: 84883767546     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.23698     Document Type: Article

References (35)

1. Van Heeswijk RP, Veldkamp A, Mulder JW, Meenhorst PL, Lange JM, Beijnen JH, Hoetelmans RM. 2001. Combination of protease inhibitors for the treatment of HIV-1-infected patients: A review of pharmacokinetics and clinical experience. Antivir Ther 6:201-229.
2. Singh R, Chang SY, Taylor LCE. 1996. In vitro metabolism of a potent HIV-protease inhibitor (141W94) using rat, monkey and human liver S9. Rapid Commun Mass Spectrom 10:1019-1026.
3. Eagling VA, Back DJ, Barry MG. 1997. Differential inhibition of cytochrome P450 isoforms by the protease inhibitors, ritonavir, saquinavir and indinavir. Br J Clin Pharmacol 44:190-194.
4. Lillibridge JH, Liang BH, Kerr BM, Webber S, Quart B, Shetty BV, Lee CA. 1998. Characterization of the selectivity and mechanism of human cytochrome P450 inhibition by the human immunodeficiency virus-protease inhibitor nelfinavir mesylate. Drug Metab Dispos 26:609-616.
5. Barry DM, Mulcahy F, Merry C, Gibbons S, Back D. 1999. Pharmacokinetics and potential interactions amongst antiretroviral agents used to treat patients with HIV infection. Clin Pharmacokinet 36:289-304.
6. Kumar GN, Jayanti V, Lee RD, Whittern DN, Uchic J, Thomas S, Johnson P, Grabowski B, Sham H, Betebenner D, Kempf DJ, Denissen JF. 1999. In vitro metabolism of the HIV-1 protease inhibitor ABT-378: Species comparison and metabolite identification. Drug Metab Dispos 27:86-91.
7. Lee CGL, Gottesman MM, Cardarelli CO, Ramachandra M, Jeang K-T, Ambudkar SV, Pastan I, Dey S. 1998. HIV-1 protease inhibitors are substrates for the MDR1 multidrug transporter. Biochemistry 37:3594-3601.
8. Woodahl EL, Yang Z, Bui T, Shen DD, Ho RJY. 2005. MDR1 G1199A polymorphism alters permeability of HIV protease inhibitors across P-glycoprotein-expressing epithelial cells. AIDS 19:1617-1625.
9. Holmstock N, Annaert P, Augustijns P. 2012. Boosting of HIV protease inhibitors by ritonavir in the intestine: The relative role of cytochrome P450 and P-glycoprotein inhibition based on Caco-2 monolayers versus in situ intestinal perfusion in mice. Drug Metab Dispos Biol Fate Chem 40:1473-1477.
10. Ye Z, Augustijns P, Annaert P. 2008. Cellular accumulation of cholyl-glycylamido-fluorescein in sandwich-cultured rat hepatocytes: Kinetic characterization, transport mechanisms, and effect of human immunodeficiency virus protease inhibitors. Drug Metab Dispos 36:1315-1321.
11. Ye Z, Camus S, Augustijns P, Annaert P. 2010. Interaction of eight HIV protease inhibitors with the canalicular efflux transporter ABCC2 (MRP2) in sandwich-cultured rat and human hepatocytes. Biopharm Drug Dispos 31:178-188.
12. Griffin L, Annaert P, Brouwer KLR. 2011. Influence of drug transport proteins on the pharmacokinetics and drug interactions of HIV protease inhibitors. J Pharm Sci 100:3636-3654.
13. Weiss J, Burhenne J, Riedel K-D, Haefeli WE. 2002. Poor solubility limiting significance of in-vitro studies with HIV protease inhibitors. AIDS 16:674-676.
14. Williams GC, Sinko PJ. 1999. Oral absorption of the HIV protease inhibitors: A current update. Adv Drug Deliv Rev 39:211-238.
15. Sharma P, Chawla A, Arora S, Pawar P. 2012. Novel drug delivery approaches on antiviral and antiretroviral agents. J Adv Pharm Technol Res 3:147-159.
16. Fabbiani M, Di Giambenedetto S, Bracciale L, Bacarelli A, Ragazzoni E, Cauda R, Navarra P, De Luca A 2009. Pharmacokinetic variability of antiretroviral drugs and correlation with virological outcome: 2 years of experience in routine clinical practice. J Antimicrob Chemother 64:109-117.
17. Dressman JB, Vertzoni M, Goumas K, Reppas C. 2007. Estimating drug solubility in the gastrointestinal tract. Adv Drug Deliv Rev 59:591-602.
18. Vertzoni M, Fotaki N, Kostewicz E, Stippler E, Leuner C, Nicolaides E, Dressman J, Reppas C. 2004. Dissolution media simulating the intralumenal composition of the small intestine: Physiological issues and practical aspects. J Pharm Pharmacol 56:453-462.
19. Clarysse S, Brouwers J, Tack J, Annaert P, Augustijns P. 2011. Intestinal drug solubility estimation based on simulated intestinal fluids: Comparison with solubility in human intestinal fluids. Eur J Pharm Sci 43:260-269.
20. Perez de la Cruz Moreno M, Oth M, Deferme S, Lammert F, Tack J, Dressman J, Augustijns P. 2006. Characterization of fasted-state human intestinal fluids collected from duodenum and jejunum. J Pharm Pharmacol 58:1079-1089.
21. Annaert P, Brouwers J, Bijnens A, Lammert F, Tack J, Augustijns P. 2010. Ex vivo permeability experiments in excised rat intestinal tissue and in vitro solubility measurements in aspirated human intestinal fluids support age-dependent oral drug absorption. Eur J Pharm Sci 39:15-22.
22. Boni JE, Brickl RS, Dressman J, Pfefferle ML. 2009. Instant FaSSIF and FeSSIF-biorelevance meets practicality. Dissolution Technol 16:41-46.
23. The United States Pharmacopeia 22, 1990 Mack Easton, Pennsylvania, 975.
24. Fagerberg JH, Tsinman O, Sun N, Tsinman K, Avdeef A, Bergström CAS. 2010. Dissolution rate and apparent solubility of poorly soluble drugs in biorelevant dissolution media. Mol Pharm 7:1419-1430.
25. Welling PG. 1996. Effects of food on drug absorption. Annu Rev Nutr 16:383-415.
26. Baldwin J, Boron M, Wang Y, Schneck D, Hopkins N. February 1-5, 1998. Chicago, USA Effects of food and antacid on bioavailability of the protease inhibitor PNU-140690 in healthy volunteers. 5th Conf Retrovir Oppor Infect.
27. Flexner C. 1998. HIV-protease inhibitors. N Engl J Med 338:1281-1292.
28. Boffito M, Maitland D, Samarasinghe Y, Pozniak A. 2005. The pharmacokinetics of HIV protease inhibitor combinations. Curr Opin Infect Dis 18:1-7.
29. Sekar V, Kestens D, Spinosa-Guzman S, De Pauw M, De Paepe E, Vangeneugden T, Lefebvre E, Hoetelmans RMW. 2007. The effect of different meal types on the pharmacokinetics of darunavir (TMC114)/ritonavir in HIV-negative healthy volunteers. J Clin Pharmacol 47:479-484.
30. Winstanley P, Orme M. 1989. The effects of food on drug bioavailability. Br J Clin Pharmacol 28:621-628.
31. Davit BM, Conner DP, Fabian-Fritsch B, Haidar SH, Jiang X, Patel DT, Seo PRH, Suh K, Thompson CL, Yu LX. 2008. Highly variable drugs: Observations from bioequivalence data submitted to the FDA for new generic drug applications. AAPS J 10:148-156.
32. Yeh KC, Deutsch PJ, Haddix H, Hesney M, Hoagland V, Ju WD, Justice SJ, Osborne B, Sterrett AT, Stone JA, Woolf E, Waldman S. 1998. Single-dose pharmacokinetics of indinavir and the effect of food. Antimicrob Agents Chemother 42:332-338.
33. Holmstock N, Bruyn TD, Bevernage J, Annaert P, Mols R, Tack J, Augustijns P. 2013. Exploring food effects on indinavir absorption with human intestinal fluids in the mouse intestine. Eur J Pharm Sci 49:27-32.
34. Lindenberg M, Kopp S, Dressman JB. 2004. Classification of orally administered drugs on the World Health Organization Model list of Essential Medicines according to the biopharmaceutics classification system. Eur J Pharm Biopharm 58:265-278.
35. Kasim NA, Whitehouse M, Ramachandran C, Bermejo M, Lennernäs H, Hussain AS, Junginger HE, Stavchansky SA, Midha KK, Shah VP, Amidon GL. 2004. Molecular properties of WHO essential drugs and provisional biopharmaceutical classification. Mol Pharm 1:85-96.